MELPHALAN HYDROCHLORIDE (melphalan hydrochloride) by Fresenius Kabi is clinical pharmacology: melphalan is an alkylating agent of the bischloroethylamine type. Approved for myeloma. First approved in 2017.
Drug data last refreshed 20h ago
CLINICAL PHARMACOLOGY: Melphalan is an alkylating agent of the bischloroethylamine type. As a result, its cytotoxicity appears to be related to the extent of its interstrand cross-linking with DNA, probably by binding at the Nposition of guanine. Like other bifunctional alkylating agents, it is…
Worked on MELPHALAN HYDROCHLORIDE at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Clinical Study of Safety and Tolerability of Melphalan Hydrochloride for R/R MM
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo